MedTrace Logo

A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany

NCT07255638 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2026-04-20

No results posted yet for this study

Summary

This is a non-interventional study assessing the effectiveness of avapritinib (BLU-285) in the management of ISM in real-world settings in Germany. The study also seeks to address the existing data gap in the natural history and management of participants with ISM.

The study is designed to follow each participant up to a maximum of 24 months.

Conditions

  • Indolent Systemic Mastocytosis

Interventions

DRUG

Avapritinib

Avapritinib will be administered as an oral tablet.

Sponsors & Collaborators

  • Blueprint Medicines Corporation

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-09
Primary Completion
2028-12-01
Completion
2028-12-01

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07255638 on ClinicalTrials.gov